期刊文献+

Combined Detection of Serum Matrix Metalloproteinase 9,Acetyl Heparinase and Cathepsin L in Diagnosis of Ovarian Cancer 被引量:4

Combined Detection of Serum Matrix Metalloproteinase 9,Acetyl Heparinase and Cathepsin L in Diagnosis of Ovarian Cancer
下载PDF
导出
摘要 Objective: To investigate the clinic values of combining test of serum matrix metalloproteinase 9 (MMP-9), acetyl heparinase (Hpa) and Cathepsin L (CL) in diagnosis of ovarian cancer. Methods: Serum levels of MMP-9, Hpa and CL were detected in a total of 418 cases, including 217 cases with ovarian malignant tumor, 100 cases with ovarian benign tumor and 101 healthy controls, by using enzyme-linked immunosorbent assay (ELISA). Their correlation with clinicopathologic feature of ovarian malignant tumor was analyzed and their diagnosis performance was evaluated by receiver operating characteristic (ROC). The combined diagnosis model was established by logistic regression analysis. Results: The serum levels of MMP-9, Hpa and CL were significantly higher in patients with ovarian malignant tumor than in benign tumor and healthy control, the serum levels of CL and Hpa were higher in epithelial cancer than in non-epithelial tumor, and MMP-9, Hpa and CL were elevated in low grade and advanced stage compared to high grade and early stage. The sensitivity for diagnosis of ovarian malignant tumor from high to low was CL, Hpa and MMP-9, and the specificity was MMP-9, CL and Hpa. The united diagnosis model was established and showed the sensitivity and specificity of combined detection were 84.6% and 82.1%, respectively, which were significantly higher than a single tumor marker. Conclusion: Serum MMP-9, Hpa and CL were correlated with ovarian malignant tumor and the combined detection of which may be valuable for clinical diagnosis of ovarian malignant tumor. Objective: To investigate the clinic values of combining test of serum matrix metalloproteinase 9 (MMP-9), acetyl heparinase (Hpa) and Cathepsin L (CL) in diagnosis of ovarian cancer. Methods: Serum levels of MMP-9, Hpa and CL were detected in a total of 418 cases, including 217 cases with ovarian malignant tumor, 100 cases with ovarian benign tumor and 101 healthy controls, by using enzyme-linked immunosorbent assay (ELISA). Their correlation with clinicopathologic feature of ovarian malignant tumor was analyzed and their diagnosis performance was evaluated by receiver operating characteristic (ROC). The combined diagnosis model was established by logistic regression analysis. Results: The serum levels of MMP-9, Hpa and CL were significantly higher in patients with ovarian malignant tumor than in benign tumor and healthy control, the serum levels of CL and Hpa were higher in epithelial cancer than in non-epithelial tumor, and MMP-9, Hpa and CL were elevated in low grade and advanced stage compared to high grade and early stage. The sensitivity for diagnosis of ovarian malignant tumor from high to low was CL, Hpa and MMP-9, and the specificity was MMP-9, CL and Hpa. The united diagnosis model was established and showed the sensitivity and specificity of combined detection were 84.6% and 82.1%, respectively, which were significantly higher than a single tumor marker. Conclusion: Serum MMP-9, Hpa and CL were correlated with ovarian malignant tumor and the combined detection of which may be valuable for clinical diagnosis of ovarian malignant tumor.
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2012年第1期67-71,共5页 中国癌症研究(英文版)
基金 supported by a grant from the Provincial Research Project Funding of Guangxi,China (No. GSR 9817101)
关键词 Ovarian cancer Matrix metalloproteinase 9 Acetyl heparinase CATHEPSIN DIAGNOSIS Ovarian cancer Matrix metalloproteinase 9 Acetyl heparinase Cathepsin Diagnosis
  • 相关文献

参考文献1

二级参考文献13

  • 1Stack MS, Ellerbroek SM, Fishman DA. The role of proteolytic enzymes in the palhology of epithelial ovarian carcinoma[ J]. Int J Oncol, 1998, 12 (3) :569 - 576.
  • 2Huang Lw, Garrett AP, Bell DA, et al. Differential expression of matrix metalleproteinase-9 and Tissue inhibitor of matrix metalleproteinase-1 protein and mRNA in epithelial ovarian tumors[ J]. Gynecol Oncol, 2000,77 (3) :369 - 376.
  • 3Parsons SL, Watson SA, Collins HM, et al. Gelatinase (MMP-2 and MMP- 9) expression in gastrointestinal malignancy[ J]. Br J Cancer, 1998,78 (11):1495- 1502.
  • 4Hoekstra R, Eskens FA, Verweij J. Matrix metalloproteinase inhibitors: current developments and future perspectives[ J ]. The Oncohgist, 2001,6 (5) :415 - 427.
  • 5Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis[ J ]. Cancer Chemotherapy and Pharmacology, 1999, 43 ( suppl ) : 42 - 51.
  • 6Sillanpaa S, Anttila M, Voutilainen K, et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer[J]. Gynecol Oncol,2007,104(2) :296 - 303.
  • 7Sakata K, Shigemasa K, Nagai N, et al. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary[J] .lnt J Oncol,2000, 17(4) :673 - 681.
  • 8Lengyel E,Schmalfeldt B,Konik E,et al. Expression of latent matrix metallo-proteinase-9 (MMP-9)predicts survival in advanced ovarian cancer [J]. Gynecol Oncol,2001,82(2) :291 - 298.
  • 9Murthi P, Barker G, Nowell CJ, et al. Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression[ J ]. Gynecol Oneol, 2004,92(1):80-88.
  • 10Demeter A, Sziller I, Csapo Z, et al. Molecular prognostic markers in recurrent and in non epithelial ovarian cancer [ J ]. Anticancer Res, 2005,25(4) :2885 - 2889.

共引文献1

同被引文献39

  • 1Hong-Wen Wu,Cheng-Yong Qin,Ji-Lai Huang,Xian-Yi Kong,Wen-Ji Wang,Wen-Kun Bai.Correlations of β-catenin,Ki67 and Her-2/neu with gastric cancer[J].Asian Pacific Journal of Tropical Medicine,2014,7(4):257-261. 被引量:1
  • 2刘诚明,程静新,段新华,萨吉旦木.买买提,桂霞,雷君,谌宏鸣.CA125、CA724检测在卵巢肿瘤诊断中的价值[J].新疆医科大学学报,2004,27(4):409-410. 被引量:3
  • 3翁彬,孟庆宝,王雷萍,段纯.肿瘤标志物联合检测诊断卵巢癌的实验研究[J].医学临床研究,2006,23(4):486-487. 被引量:17
  • 4葛学顺.CA125、CA199联合检测对卵巢恶性肿瘤的诊断价值[J].检验医学与临床,2007,4(3):177-177. 被引量:23
  • 5Shyam S,Chauhan LJG?Michael MG.Expression of ca-thepsin L in human tumors[J].Cancer Res,1991,51:1478-1481.
  • 6Sasa Kenig,Robert Frangez,Anja Pucer?et al.Inhibitionof cathepsin L lowers the apoptotic threshold of glio-blastoma cells by up-regulating P53 and transcription ofcaspases 3 and 7[J],Apoptosis,2011,16(7):671-682.
  • 7Nishida Y,Kohno K,Kawamata T,et al.Increased ca-thepsin L levels in serum in some patients with ovariancancer:comparison with CA125 and CA724[J].Gyne-col Oncol,1995,56(3):357-361.
  • 8Eva Kolwijck,Leon FAG,Massuger,et al.CathepsinsB,L and cystatin C in cyst fluid of ovarian tumors[J].J Cancer Res Clin Oncol,2010,136(5):771-778.
  • 9Niedergethmann M,Wostbrock B,Strum JW,et al.Prognostic imPact of cysteine Protease cathepsin B andcathepsin L in pancreatic adenocarcinoma[J].Pancre-ase,2004,29(3):204-211.
  • 10Maricris M,Caroline H,Shiboski Sol,et al.Quantitativeanalysis of cathepsin L mRNA and protein,expressionduring oral cancer progression[J].Oral 0nco,2003,39(6):638-647.

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部